株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

子宮内膜症治療薬の予測およびR&D 2016-2026年:一般的な女性生殖器系疾患治療市場における収益の拡大

Endometriosis Drug Forecasts and R&D 2016-2026: Revenues of That Expanding Market for Treating a Prevalent Women's Reproductive System Disorder

発行 Visiongain Ltd 商品コード 351720
出版日 ページ情報 英文 142 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1GBP=146.92円で換算しております。

ご注意:
Single UserとDepartmentalライセンスは、DRM (デジタル著作権管理システム) 付PDFになります。制限内容は、上記ライセンスの[?]アイコンをクリックしてご確認ください。

Back to Top
子宮内膜症治療薬の予測およびR&D 2016-2026年:一般的な女性生殖器系疾患治療市場における収益の拡大 Endometriosis Drug Forecasts and R&D 2016-2026: Revenues of That Expanding Market for Treating a Prevalent Women's Reproductive System Disorder
出版日: 2016年02月05日 ページ情報: 英文 142 Pages
概要

世界の女性の10%が子宮内膜症を患っており、治療薬の需要は高まっています。世界の子宮内膜症治療薬市場は、2020年に19億2,000万米ドルに達すると予測されています。2016年から2026年にかけて拡大が見込まれています。

当レポートでは、世界の子宮内膜症治療薬市場について調査し、世界市場全体の子宮内膜症治療薬の収益予測、主要企業の売上予測、主要国市場の予測、研究開発動向、および市場影響因子などについて、分析しています。

第1章 レポート概要

第2章 子宮内膜症とその治療のイントロダクション

  • 子宮内膜症とは?
  • 婦人科疾患の発生率・有病率
  • 子宮内膜症治療薬市場
  • PEST分析
  • 市場成長促進因子・抑制因子
  • 子宮内膜症治療薬市場の展望

第3章 主要国市場:展望

  • 子宮内膜症治療:治療法別
    • ホルモン治療
    • 鎮痛剤
    • 外科治療
  • 主要国の子宮内膜症市場
    • 主要国市場:米国が独占
    • 主要国市場の将来は?
    • 米国の子宮内膜症市場
    • EU5ヵ国の子宮内膜症市場
    • 日本の子宮内膜症市場:世界第2位の市場
    • 中国の子宮内膜症市場
    • インドの子宮内膜症市場:急成長市場
    • ブラジルの子宮内膜症市場
    • ロシアの子宮内膜症市場

第4章 世界の子宮内膜症市場における主要な治療薬

  • Lupron:市場における第1位の子宮内膜症治療薬
    • プロファイル
    • 収益実績
    • 収益予測
  • Eligard:特許期限切れの際に直面する課題
  • Zoladex
  • Depo-Provera
  • Visanne:Bayerによる子宮内膜症向けの最初の経口療法

第5章 子宮内膜症治療薬の研究開発

  • 産業連携・R&D活動
  • 子宮内膜症向け治療薬の生産に関わる企業
  • AbbVie:子宮内膜症治療薬のトップメーカー
  • Pfizer
  • Bayer HealthCare
  • AstraZeneca
  • アステラス製薬
  • 武田薬品鉱業
  • Repros Therapeutics
  • Euroscreen
  • キッセイ薬品
  • Addex Therapeutics

第6章 子宮内膜症治療薬市場の定性分析

  • SWOT分析
  • 市場の強味
  • 弱み
  • 機会
  • 脅威

第7章 調査インタビュー

第8章 結論

  • 子宮内膜症治療薬市場の将来
  • 米国は引き続き国別の最大市場にとどまる
  • 子宮内膜症治療薬市場の動向

図表

目次
Product Code: PHA0088

Endometriosis Medicines - Your 2016 Guide to Sales Potentials of that Rising, Underserved Female Health Market

What does the future hold for treating endometriosis, a common disease? Our new analysis forecasts sales of drugs treating that menstrual cycle disorder. Visiongain's report gives predictions to 2026 at overall world market, product and national level.

Avoid falling behind in data or losing influence. Instead discover what progress, opportunities and increasing revenues endometrial therapies face. There you also explore trends, results, R&D and events, assessing commercial prospects.

Read on, then, to explore endometriosis treatments, including hormonal therapy. See below what future revenue that expanding pharmaceuticals market could generate.

Forecasts and other analysis to benefit your research, assessments, plans and decisions

10% of women worldwide have endometriosis, giving high, rising demand for those medicines. New drugs appear and promising candidates reach clinical trials. Discover, from 2016, what revenues and other progress are possible in that expanding market.

Besides sales forecasting to 2026, our survey shows recent results, growth rates and market shares. There you find original analysis. You also assess research and development. The study gives 53 tables, 61 charts and a research interview.

Our report's purpose is to help your research, analyses and decisions on the endometriosis drugs industry and market. Our work also benefits your authority and reputation for commercial insight, helping you compete and succeed.

The following sections explain how our new investigation benefits your work.

Predictions of drug sales - what is possible for those gynaecological medicines?

How will endometriosis medicines perform from 2015 to 2026 at world level? Our study forecasts revenues of these five brands:

  • Lupron
  • Eligard
  • Zoladex
  • Depo-Provera
  • Visanne.

Our analysis shows how products can compete and succeed. There you investigate trends, exploring challenges, changes and opportunities. See what is possible.

Discover what the future holds for endometriosis drugs and their developers, producers and marketers.

Endometriosis R&D holds high potential - explore advances, assessing prospects

That therapeutic segment holds much promising research and development. The new gonadotropin-releasing hormone (GnRH) antagonist approach to treat endometriosis may take over from the present GnRH agonist drugs, our study notes.

There exists great scope for new and improved medicines, benefiting pharma companies, healthcare providers and patients. Explore, from 2016, what is possible, staying ahead in knowledge to benefit your work.

Our report also shows you geographical sales predictions.

National markets - what is possible for those gynaecological drug revenues?

Advances in biopharma expand the range and use of endometriosis-treating drugs. Our study shows you individual revenue forecasts to 2026 for 11 national markets:

  • US
  • Japan
  • Germany, France, Italy, Spain, UK (EU5)
  • China, Brazil, India, Russia (BRIC).

That way you assess countries and regions with highest revenues and potential sales growth. See what is possible, from 2016, in developed and developing countries.

That market gains momentum from rising disease prevalence, new and improved drugs and other forces stimulating treatment demand in that under-served market.

Influences, events and changes affecting companies treating endometriosis

Explore issues affecting that market, including these forces:

  • Incidence and prevalence of that disorder, an often overlooked condition
  • Raising disease awareness and overcoming reimbursement challenges
  • Improving diagnosis and treatment of endometriosis - new therapies controlling hormones responsible for the build-up of endometrial tissue
  • Hormone therapy, pain relievers (e.g. NSAIDs), contraceptives, medical devices and surgical options.

And gain insight on these developments, among others:

  • Prospects for leading and emerging national markets - what the future holds for treating those vast patient populations
  • Oral drug delivery for endometriosis - new therapies and novel drug candidates extend therapeutic and commercial potentials of that market
  • Industry collaborations and R&D activities that stimulate progress.

In our report you also gain SWOT and PEST analysis, assessing what drives and restrains that expanding female health market.

That way you discover what is possible for leading pharma companies and specialists. Why miss out? Instead explore what the future holds for treating endometriosis, seeing the gains possible.

Leading companies and overall 2020 market value - what revenues are possible?

Our work predicts the world market for those drugs will reach $1.92 billion in 2020. That market will expand from 2016 to 2026. With our analysis you discover how high sales can go, seeing what is possible for those drug companies.

That way you assess what organisations hold most potential. Those companies include these organisations:

  • AbbVie
  • Pfizer
  • Bayer HealthCare
  • AstraZeneca
  • Astellas
  • Takeda.

Discover what the future holds for participants in that industry, exploring what they do, as well as their commercial potentials.

6 ways Endometriosis Drug Forecasts and R&D 2016-2026 helps your work

Our new investigation benefits your work in these six main ways, helping you stay ahead in knowledge and benefit your authority:

  • Revenues for endometriosis drugs at overall world level to 2026 - assess scope for investments, developments, production and marketing
  • Leading products' sales to 2026 - discover predicted revenues of 5 prominent drugs, seeing how those medicines can compete and succeed
  • National market forecasting to 2026 for 11 leading countries - explore the best regions for treatment demand, sales and revenue expansion
  • Research and development - see progress, trends and prospects in that gynaecological R&D, assessing opportunities and possibilities
  • Leading companies, news and opinion - examine participants in that rising market, gaining insight to help you stay ahead and succeed
  • Analysis of what stimulates and restrains that market - assess challenges and strengths, helping you compete and gain advantages.

That analysis, by our in-house team in the UK, gives knowledge to benefit your research, plans, decisions and proposals. It shows data you find nowhere else.

Predictions for that female reproductive disorder - benefit your reputation for insight

With our independent study you assess products, companies, progress and possibilities for that female reproductive medicine. There discover the best commercial opportunities, as well as ways to help patients. See what is possible.

Having our analysis means you are less likely to fall behind in knowledge or miss opportunity. Through your choice now, find how to save time and effort, also benefiting your plans, decisions, presentations, proposals and influence.

Try that study, staying ahead. Our investigation shows you data, trends, opportunities and forecasts for that large, expanding female healthcare market. So avoid missing out - please get our new report here now.

visiongain is a trading partner with the US Federal Government

Table of Contents

1. Report Overview

  • 1.1. Endometriosis Drugs: Industry and Market Review
  • 1.2. Benefits of This Report
  • 1.3. How This Study Delivers
  • 1.4. Main Questions This Work Answers
  • 1.5. Who is This Report For?
  • 1.6. Methods of Research and Analysis
  • 1.7. Frequently Asked Questions (FAQ)
  • 1.8. Some Related Reports
  • 1.9. About Visiongain

2. Introduction to Endometriosis and its Treatment

  • 2.1. What is Endometriosis?
  • 2.2. Incidence and Prevalence of that Female Disorder
  • 2.3. The Endometriosis Drug Market, 2014
  • 2.4. PEST Analysis
    • 2.4.1. Political Factors
    • 2.4.2. Economic Factors
    • 2.4.3. Social Factors Affecting the Endometriosis Therapies Market
    • 2.4.4. Technological Developments in Endometriosis Treatment
  • 2.5. Market Growth Drivers and Restraints
  • 2.6. Outlook for the Endometriosis Drugs Market, 2015-2026

3. Leading National Markets: Outlooks, 2016-2026

  • 3.1. Endometriosis Treatment by Therapy
    • 3.1.1. Hormones
    • 3.1.2. Painkillers
    • 3.1.3. Surgical Treatment
  • 3.2. Endometriosis Leading National Markets, 2016-2026
    • 3.2.1. Leading National Markets: The US Dominated in 2014
    • 3.2.2. What is The Future for Leading National Markets?
    • 3.2.3. The US Endometriosis Market, 2016 to 2026
    • 3.2.4. EU5 Endometriosis Market, 2016 to 2026
      • 3.2.4.1. The UK Endometriosis Market, 2016 to 2026
      • 3.2.4.2. French Endometriosis Market, 2016 to 2026: Steady Growth Throughout the Forecast Period
      • 3.2.4.3. German Endometriosis Market, 2016 to 2026: Largest Market Share in European Union
      • 3.2.4.4. Spanish Endometriosis Market, 2016 to 2026
      • 3.2.4.5. Italian Endometriosis Market, 2016 to 2026
    • 3.2.5. Japanese Endometriosis Market, 2016 to 2026: Second Largest in the World
    • 3.2.6. Chinese Endometriosis Market, 2016 to 2026
    • 3.2.7. Indian Endometriosis Market, 2016 to 2026: Fast Growing Market
    • 3.2.8. Brazilian Endometriosis Market, 2016 to 2026
    • 3.2.9. Russian Endometriosis Market, 2016 to 2026

4. Leading Drugs in the World Endometriosis Market, 2015

  • 4.1. Lupron: The Leading Endometriosis Drug in the Market
    • 4.1.1. Profile
    • 4.1.2. Lupron Historical Revenue
    • 4.1.3. Lupron Revenue Forecast, 2016-2026
  • 4.2. Eligard: Facing Challenges When Patent Expires
    • 4.2.1. Profile
    • 4.2.2. Eligard Historical Revenue
    • 4.2.3. Eligard Revenue Forecast, 2016-2026
  • 4.3. Zoladex
    • 4.3.1. Profile
    • 4.3.2. Zoladex Historical Revenue
    • 4.3.3. Zoladex Revenue Forecast, 2016-2026
  • 4.4. Depo-Provera
    • 4.4.1. Profile
    • 4.4.2. Depo-Provera Historical Revenue
    • 4.4.3. Depo-Provera Forecast, 2016 to 2026
  • 4.5. Visanne: First Oral Treatment for Endometriosis by Bayer
    • 4.5.1. Profile
    • 4.5.2. Visanne Historical Revenue
    • 4.5.3. Visanne Forecast, 2016 to 2026

5. Research and Development for Endometriosis Drugs

  • 5.1. Industry Collaboration and R&D Activities
    • 5.1.1. Investigational Drug Treatment for Endometriosis
  • 5.2. Companies Involved in Producing Drugs for Endometriosis
  • 5.3. AbbVie: Leading Producer of Endometriosis Drugs
    • 5.3.1. Company Description
    • 5.3.2. Business Segmentation
    • 5.3.3. AbbVie Revenue Performance, 2014
    • 5.3.4. Product in Pipeline: Elagolix, Oral Drug
  • 5.4. Pfizer
    • 5.4.1. Company Description
    • 5.4.2. Business Segmentation
    • 5.4.3. Pfizer Revenue Performance, 2014
  • 5.5. Bayer HealthCare: Visanne Showing Faster Growth in Revenue
    • 5.5.1. Company Description
    • 5.5.2. Business Segmentation
    • 5.5.3. Bayer HealthCare Revenue Performance, 2014
    • 5.5.4. Four Drug Candidates in Product Pipeline
  • 5.6. AstraZeneca
    • 5.6.1. Company Description
    • 5.6.2. Business Segmentation
    • 5.6.3. AstraZeneca Revenue Performance, 2014
  • 5.7. Astellas
    • 5.7.1. Company Description
    • 5.7.2. Business Segmentation
    • 5.7.3. ASP1707 an Oral Dosage Form: Product in Pipeline
  • 5.8. Takeda
    • 5.8.1. Company Description
    • 5.8.2. Business Segmentation
    • 5.8.3. Product in Pipeline: Relugolix- Oral Form
  • 5.9. Repros Therapeutics
    • 5.9.1. Company Description
    • 5.9.2. Business Segmentation
    • 5.9.3. Product in Pipeline: Proellex in Phase II Trials
  • 5.10. Euroscreen
    • 5.10.1. Company Description
    • 5.10.2. Business Segmentation
    • 5.10.3. Product in Pipeline: ESN364 Has Entered Into Phase II Trials
  • 5.11. Kissei Pharmaceutical
    • 5.11.1. Company Description
    • 5.11.2. Business Segmentation
    • 5.11.3. Product in Pipeline: KLH-2109 Exclusive Rights Given to ObsEva
  • 5.12. Addex Therapeutics
    • 5.12.1. Company Description
    • 5.12.2. Product in Pipeline

6. Qualitative Analysis of the Endometriosis Drugs Market

  • 6.1. SWOT Analysis: Future Scope of the Market
  • 6.2. Strengths of the Market
    • 6.2.1. Vast, Expanding Ageing Population
    • 6.2.2. A Number of Promising Drug Candidates
    • 6.2.3. Secondary Indications
  • 6.3. Weaknesses
    • 6.3.1. Lack of Disease Awareness
    • 6.3.2. Reimbursement Issues
    • 6.3.3. Demand for Better Diagnosis and Treatment of Endometriosis
  • 6.4. Opportunities
    • 6.4.1. Rising Disease Prevalence
    • 6.4.2. Increased Demand in Market
    • 6.4.3. Novel Mechanisms and Delivery Methods
  • 6.5. Threats
    • 6.5.1. Competition from Generic Drugs
    • 6.5.2. Governments Limiting Healthcare Spending

7. Research Interview

  • 7.1. Interview with Mr Kumar Kunde, Consultant Obstetrician and Gynaecologist, Guy's and St Thomas' Private Healthcare, UK

8. Conclusions from the Research and Analysis

  • 8.1. Future of the Endometriosis Pharmaceuticals Market
  • 8.2. The US Will Remain the Largest National Market from 2016 to 2026
  • 8.3. Trends in the Endometriosis Treatments Market

List of Tables

  • Table 1.1: Endometriosis Drug Sales: Leading National Markets, Revenue ($m), AGR (%) and CAGR (%), 2015-2026
  • Table 1.2: Currency Exchange Rate to $US
  • Table 2.1: Prevalence of Endometriosis in Women: Leading Countries, 2014
  • Table 2.2: Global Endometriosis Market Revenue Performance: Revenue ($bn) and AGR (%), 2012-2014
  • Table 2.3: Political, Economic, Social and Technological Factors (PEST) Affecting Endometriosis Market, 2016
  • Table 2.4: Global Endometriosis Market: Revenues ($m), Annual Growth Rate (%), CAGR (%), 2014-2020
  • Table 2.5: Global Endometriosis Market: Revenues ($m), Annual Growth Rate (%), CAGR (%), 2020-2026
  • Table 3.1: Endometriosis Leading National Markets: Revenue ($m) and Market Share (%), 2014
  • Table 3.2: Endometriosis Leading National Markets Forecast: Revenue ($m), AGR (%) and CAGR (%), 2015-2026
  • Table 3.3: Market Share (%) and Revenue ($m) Comparison of the Leading Endometriosis Therapeutic National Markets, 2015, 2020 and 2026
  • Table 3.4: The US Endometriosis Therapeutic Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2014-2020
  • Table 3.5: The US Endometriosis Therapeutic Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2020-2026
  • Table 3.6: EU5 Endometriosis Therapeutic Market Forecasts by Country: Revenue ($m), AGR (%), CAGR (%), 2014-2026
  • Table 3.7: The UK Endometriosis Therapeutic Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2014-2020
  • Table 3.8: The UK Endometriosis Therapeutic Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2020-2026
  • Table 3.9: French Endometriosis Therapeutic Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2014-2020
  • Table 3.10: French Endometriosis Therapeutic Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2020-2026
  • Table 3.11: German Endometriosis Therapeutic Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2014-2020
  • Table 3.12: German Endometriosis Therapeutic Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2020-2026
  • Table 3.13: Spanish Endometriosis Therapeutic Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2014-2020
  • Table 3.14: Spanish Endometriosis Therapeutic Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2020-2026
  • Table 3.15: Italian Endometriosis Therapeutic Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2014-2020
  • Table 3.16: Italian Endometriosis Therapeutic Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2020-2026
  • Table 3.17: Japanese Endometriosis Therapeutic Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2014-2020
  • Table 3.18: Japanese Endometriosis Therapeutic Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2020-2026
  • Table 3.19: Chinese Endometriosis Therapeutic Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2014-2020
  • Table 3.20: Chinese Endometriosis Therapeutic Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2020-2026
  • Table 3.21: Indian Endometriosis Therapeutic Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2014-2020
  • Table 3.22: Indian Endometriosis Therapeutic Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2020-2026
  • Table 3.23: Brazilian Endometriosis Therapeutic Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2014-2020
  • Table 3.24: Brazilian Endometriosis Therapeutic Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2020-2026
  • Table 3.25: Russian Endometriosis Therapeutic Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2014-2020
  • Table 3.26: Russian Endometriosis Therapeutic Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2020-2026
  • Table 4.1: The Endometriosis Drug Market: Revenue ($m), Revenue Share (%) by Leading Drugs, 2014, 2020, 2026
  • Table 4.2: Endometriosis Market: Forecasts by Leading Drugs, Revenue ($m), AGR (%), CAGR (%), 2015-2026
  • Table 4.3: Lupron Revenue Segmentation: Revenue ($m), Revenue Share (%), 2014
  • Table 4.4: Lupron Historical Revenue ($m), Annual Growth (%) and CAGR (%), 2011-2014
  • Table 4.5: Lupron Forecast: Revenue ($m), Annual Growth (%) and CAGR (%), 2015-2026
  • Table 4.6: Eligard Revenue Segmentation: Revenue ($m), Revenue Share (%), 2014
  • Table 4.7: Eligard Historical Revenue ($m), Annual Growth (%) and CAGR (%), 2011-2014
  • Table 4.8: Eligard Forecast: Revenue ($m), Annual Growth (%) and CAGR (%), 2015-2026
  • Table 4.9: Zoladex Revenue Segmentation: Revenue ($m), Revenue Share (%), 2014
  • Table 4.10: Zoladex Historical Revenue ($m), Annual Growth (%) and CAGR (%), 2011-2014
  • Table 4.11: Zoladex Forecast: Revenue ($m), Annual Growth (%) and CAGR (%), 2015-2026
  • Table 4.12: Depo-Provera Revenue Segmentation: Revenue ($m), Revenue Share (%), 2014
  • Table 4.13: Depo-Provera Historical Revenue ($m), Annual Growth (%) and CAGR (%), 2011-2014
  • Table 4.14: Depo-Provera Forecast: Revenue ($m), Annual Growth (%) and CAGR (%), 2015-2026
  • Table 4.15: Visanne Historical Revenue ($m), Annual Growth (%) and CAGR (%), 2011-2014
  • Table 4.16: Visanne Forecast: Revenue ($m), Annual Growth (%) and CAGR (%), 2015-2026
  • Table 5.1: AbbVie: Drug Revenue ($m) and Change (%), 2013 and 2014
  • Table 5.2: AbbVie: Drug Revenue ($m) and Drug Revenue Share (%), 2014
  • Table 5.3: Pfizer: Drug Revenue ($m) and Drug Revenue Share (%), 2014
  • Table 5.4: Bayer: Revenue ($m) and Revenue Share (%) Based on Business Segment, 2014
  • Table 5.5: Bayer: Drug Revenue ($m) and Drug Revenue Share (%), 2014
  • Table 5.6: AstraZeneca: Revenue ($m) and Revenue Share (%) Based on Business Segments, 2014

List of Figures

  • Figure 2.1: Prevalence of Endometriosis in Women (in Millions), Leading Countries, 2014
  • Figure 2.2: Global Endometriosis Market Revenue Performance: Revenue ($bn), 2012-2014
  • Figure 2.3: Global Endometriosis Market: Drivers and Restraints, 2014-2026
  • Figure 2.4: Forecast Global Endometriosis Market: Revenue ($m), 2014-2020
  • Figure 2.5: Forecast Global Endometriosis Market: Revenue ($m), 2020-2026
  • Figure 3.1: Endometriosis Leading National Markets: Shares (%), 2014
  • Figure 3.2: Endometriosis Leading National Markets: Shares (%), 2015
  • Figure 3.3: Endometriosis Leading National Markets: Shares (%), 2020
  • Figure 3.4: Endometriosis Leading National Markets: Shares (%), 2026
  • Figure 3.5: The US Endometriosis Therapeutic Market Forecast: Revenue ($m), 2014-2020
  • Figure 3.6: The US Endometriosis Therapeutic Market Forecast: Revenue ($m), 2020-2026
  • Figure 3.7: EU5 Endometriosis Therapeutic Market: Overall Revenue ($m), 2014-2026
  • Figure 3.8: EU5 Endometriosis Therapeutic Markets: National Shares (%), 2014, 2020 and 2026
  • Figure 3.9: EU5 Endometriosis Therapeutic Market Forecast: Revenue ($m) Breakdown by Countries, 2014-2026
  • Figure 3.10: The UK Endometriosis Therapeutic Market Forecast: Revenue ($m), 2014-2020
  • Figure 3.11: The UK Endometriosis Therapeutic Market Forecast: Revenue ($m), 2020-2026
  • Figure 3.12: French Endometriosis Therapeutic Market Forecast: Revenue ($m), 2014-2020
  • Figure 3.13: French Endometriosis Therapeutic Market Forecast: Revenue ($m), 2020-2026
  • Figure 3.14: German Endometriosis Therapeutic Market Forecast: Revenue ($m), 2014-2020
  • Figure 3.15: German Endometriosis Therapeutic Market Forecast: Revenue ($m), 2020-2026
  • Figure 3.16: Spanish Endometriosis Therapeutic Market Forecast: Revenue ($m), 2014-2020
  • Figure 3.17: Spanish Endometriosis Therapeutic Market Forecast: Revenue ($m), 2020-2026
  • Figure 3.18: Italian Endometriosis Therapeutic Market Forecast: Revenue ($m), 2014-2020
  • Figure 3.19: Italian Endometriosis Therapeutic Market Forecast: Revenue ($m), 2020-2026
  • Figure 3.20: Japanese Endometriosis Therapeutic Market Forecast: Revenue ($m), 2014-2020
  • Figure 3.21: Japanese Endometriosis Therapeutic Market Forecast: Revenue ($m), 2020-2026
  • Figure 3.22: Chinese Endometriosis Therapeutic Market Forecast: Revenue ($m), 2014-2020
  • Figure 3.23: Chinese Endometriosis Therapeutic Market Forecast: Revenue ($m), 2020-2026
  • Figure 3.24: Indian Endometriosis Therapeutic Market Forecast: Revenue ($m), 2014-2020
  • Figure 3.25: Indian Endometriosis Therapeutic Market Forecast: Revenue ($m), 2020-2026
  • Figure 3.26: Brazilian Endometriosis Therapeutic Market Forecast: Revenue ($m), 2014-2020
  • Figure 3.27: Brazilian Endometriosis Therapeutic Market Forecast: Revenue ($m), 2020-2026
  • Figure 3.28: Russian Endometriosis Therapeutic Market Forecast: Revenue ($m), 2014-2020
  • Figure 3.29: Russian Endometriosis Therapeutic Market Forecast: Revenue ($m), 2020-2026
  • Figure 4.1: Endometriosis Drug Market: Revenue ($m) by Leading Drug, 2014
  • Figure 4.2: Endometriosis Drug Market: Revenue Share (%) by Leading Drugs, 2014
  • Figure 4.3: Endometriosis Drug Market: Revenue Share (%) by Leading Drugs, 2020
  • Figure 4.4: Endometriosis Drug Market: Revenue Share (%) by Leading Drugs, 2026
  • Figure 4.5: Lupron Revenue Segmentation: Revenue Share (%), 2014
  • Figure 4.6: Lupron Historical Revenue ($m), 2011-2014
  • Figure 4.7: Lupron Revenue ($m) Forecast, 2015-2026
  • Figure 4.8: Eligard Revenue Segmentation: Revenue Share (%), 2014
  • Figure 4.9: Eligard Historical Revenue ($m), 2011-2014
  • Figure 4.10: Eligard Revenue ($m) Forecast, 2015-2026
  • Figure 4.11: Zoladex Revenue Segmentation: Revenue Share (%), 2014
  • Figure 4.12: Zoladex Historical Revenue ($m), 2011-2014
  • Figure 4.13: Zoladex Revenue ($m) Forecast, 2015-2026
  • Figure 4.14: Depo-Provera Revenue Segmentation: Revenue Share (%), 2014
  • Figure 4.15: Depo-Provera Historical Revenue ($m), 2011-2014
  • Figure 4.16: Depo-Provera Revenue ($m) Forecast, 2015-2026
  • Figure 4.17: Visanne Historical Revenue ($m), 2011-2014
  • Figure 4.18: Visanne Revenue ($m) Forecast, 2015-2026
  • Figure 5.1: AbbVie: Therapeutic Focus Areas, 2014
  • Figure 5.2: AbbVie: Revenue Share (%) for Lupron, 2014
  • Figure 5.3: Pfizer: Revenue ($m) by Business Segment, 2014
  • Figure 5.4: Pfizer: Revenue Share (%) by Business Segment, 2014
  • Figure 5.5: Bayer: Revenue Share (%) by Drugs, 2014
  • Figure 5.6: Bayer: Revenue Share ($m) by Drugs, 2014
  • Figure 5.7: AstraZeneca: Revenue ($m) by Segment, 2014
  • Figure 5.8: AstraZeneca: Revenue Share of Drugs (%), 2014
  • Figure 5.9: AstraZeneca: Revenue ($m) by Drugs, 2014

Companies Listed

  • Abbott Laboratories
  • AbbVie
  • Addex Therapeutics
  • AEterna Zenaris
  • Aljazeera Hospital
  • Amanouchi Pharmaceutical Co.
  • AP Avadis Biotechnologies
  • Astellas Pharma
  • AstraZeneca
  • Atrix Laboratories
  • Australian National University
  • Bayer HealthCare
  • Brigham and Women's Hospital
  • Centre for Endocrinology and Reproductive Medicine
  • Centre for Epidemiology and Health Research
  • Children's Hospital Boston
  • Dongkook Pharmaceutical Co.
  • ElexoPharm GmbH
  • Eli Lilly
  • EndoCeutics
  • Euroscreen
  • Evotec
  • Florida Hospital
  • Food and Drug Administration (FDA)
  • Fujisawa Pharmaceutical Co.
  • GlaxoSmithKline
  • Highland Clinical Research
  • Inc. Forendo Pharma Oy
  • Indian Brand Equity Foundation
  • Instituto de Investigacion Sanitaria La Fe
  • Isifer AB
  • Jacksonville Centre for Clinical Research
  • Jiangsu Kanion Pharmaceutical Co.
  • Kissei Pharmaceutical
  • Lipicard Technologies Limited
  • Medigene AG
  • Meditrina Pharmaceuticals
  • National Health Service
  • National Institute for Clinical Excellence
  • National Institute of Health
  • Neurocrine Biosciences
  • Northwestern University
  • ObsEva
  • Orphagen Pharmaceuticals
  • Pfizer
  • Philogen
  • PregLem SA
  • Repros Therapeutics
  • Research OutSmarts Endometriosis
  • Roche
  • Sanofi
  • Schering AG
  • SK Chemicals Co.
  • Takeda Pharmaceutical
  • Tolmar Therapeutics
  • Turku University Hospital
  • University Hospital (Angers)
  • University Hospital (Mo)
  • University Hospital (Rouen)
  • University of Arhus
  • University of Athens
  • University of Cagliari
  • University of Illinois
  • University of North Carolina
  • University of Oxford
  • ValiRX
  • Women's Health Care at Frost Street
Back to Top